Connor Clark & Lunn Investment Management Ltd. increased its holdings in Nuvation Bio Inc. (NYSE:NUVB – Free Report) by 6.4% ...

JonesResearch analyst Danya Ben-Hail initiated coverage of Nuvation Bio (NUVB) with a Buy rating and $10 price target The company is focused on developing clinical stage targeted therapeutics with ...

Fintel reports that on March 12, 2025, Jones Trading initiated coverage of Nuvation Bio (NYSE:NUVB) with a Buy recommendation ...

EST Nuvation Bio (NUVB) files automatic mixed securities shelfDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are ...

In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other most oversold penny stocks to buy according to analysts. Small Cap Stocks Outlook 2025 In ...

Nuvation Bio has secured $250m in non-dilutive financing from Sagard Healthcare Partners to fully fund the commercialisation of taletrectinib in the US. The financial move will support Nuvation ...

Life science firm Nuvation Bio raised $250 million to bring its novel lung cancer therapy to market and help it reach profitability, the company said Monday. The Midtown biotech secured royalty ...

Nuvation Bio to receive $150 million in royalty interest financing and $50 million in debt upon U.S. FDA approval of taletrectinib, with access to additional $50 million in debt at the Company’s ...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder ...